Kostaki Dimitra, Aquila Emilia, Macaluso Laura, Mattozzi Carlo, Richetta Antonio Giovanni
Department of Dermatology, University of Rome, "La Sapienza", Rome, Italy.
Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):17-22. doi: 10.1159/000501994. eCollection 2019 Sep-Dec.
The introduction of biologic drugs for the treatment of moderate-to-severe psoriasis resulted in a significant improvement in patients' health. Moreover, treatment regimens in psoriatic patients should be tailored to meet specific needs based on disease severity, impact on quality of life, response to previous therapies and presence of comorbidities. Combination therapy of biologic agents with conventional systemic drugs has been proposed to optimize psoriasis treatment outcomes in unresponsive or partial responsive severe psoriatic patients. We report the case of a patient with a long-standing recalcitrant plaque psoriasis and psoriatic arthritis who was administered secukinumab combined with methotrexate. The patient had previously been treated with several topical and systemic therapies associated with loss of efficacy or adverse event occurrence. Approximately 24 weeks after starting the combined regimen, significant clearance of psoriasis and reduction of arthritis ensued, with no drug side effects.
用于治疗中重度银屑病的生物药物的引入显著改善了患者的健康状况。此外，银屑病患者的治疗方案应根据疾病严重程度、对生活质量的影响、对先前治疗的反应以及合并症的存在进行调整，以满足特定需求。有人提出将生物制剂与传统全身药物联合使用，以优化对无反应或部分反应的重度银屑病患者的治疗效果。我们报告了一例长期顽固性斑块状银屑病和银屑病关节炎患者，该患者接受了司库奇尤单抗联合甲氨蝶呤治疗。该患者此前曾接受过多种局部和全身治疗，但均出现疗效丧失或不良事件。开始联合治疗方案约24周后，银屑病显著消退，关节炎减轻，且无药物副作用。
